34 research outputs found

    The Changing Roles of Natural Resource Professionals: Providing Tools to Students to Teach the Public About Fire

    Get PDF
    The Arthur Temple College of Forestry and Agriculture (ATCOFA) at Stephen F. Austin State University is taking a proactive stance toward preparing forestry students to work closely with the public on fire planning in wildland-urban interface areas. ATCOFA\u27s incorporation of the Changing Roles curriculum provides lessons on how natural resource managers\u27 roles are (1) different than they used to be, and (2) ever-evolving. The undergraduate Forestry Field Station summer program at the University\u27s Piney Woods Conservation Center now emphasizes the importance and challenges of working with the public. The program brings practicing professionals from the Texas Forest Service to describe the real-world challenges they face in communicating and working effectively with the public in their jobs

    Producing “Society-Ready” Foresters: A Research-Based Process to Revise the Bachelor of Science in Forestry Curriculum at Stephen F. Austin State University

    Get PDF
    “Society-ready” foresters are capable of dealing effectively with the complex economic, ecological, and social issues involving forestry in the 21st century. To assess the knowledge areas, skill sets, abilities, and behaviors needed by society-ready, entry-level foresters today, we surveyed 800 forestry employers and forestry alumni from Stephen F. Austin State University (SFASU), and we also conducted focus group sessions with a total of 58 forestry employers. Important areas of knowledge on emerging issues for society-ready Bachelor of Science in Forestry (BSF) graduates included climate change, water availability and quality, and dealing with invasive plants, pathogens, and insects. However, the skill sets and abilities that involve dealing effectively with people were ranked highest in terms of areas in which the BSF curriculum at SFASU should be strengthened. This basic message—the need to improve people skills while maintaining strength and relevance in technical skills—is consistent with reports, studies, and conferences on forestry education in the United States since the early 1900s. At SFASU, we are revising the BSF curriculum to address the results of our research-based process, and we are also targeting research and outreach to address the century-old, chronic issue of how to measurably improve the knowledge, skills, abilities, and behaviors needed for foresters to work most effectively with people. In our research and application of results, we learned that the process of curriculum revision is just as important as the product: learning from our process will help guide other program leaders in forestry and natural resources to evaluate and revise undergraduate curricula. When done well, we believe work of this type will strengthen both the rigor and relevance in a curriculum, and the process will also strengthen relationships with alumni, employers, and other key constituents

    Survey of Backcountry Campers in Yellowstone National Park. Characteristics and Management Preferences (Abstract)

    Get PDF
    The identification of the complexities of the sociological dynamics of visitors and visitor use in our national parks has been a challenge to the field of human dimensions for the past thirty years. We continue to gather data through a variety of techniques and attempt to make sense of those complexities to help guide current and future management practices . .

    ATCOFA Monograph 1-2014

    Get PDF
    Producing ‘Society-ready’ Foresters: A Research-based Process to Revise the Bachelor of Science in Forestry Curriculum at Stephen F. Austin State Universityhttps://scholarworks.sfasu.edu/atcofa_monograph_series/1000/thumbnail.jp

    Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

    Get PDF
    Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

    Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

    Get PDF
    Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

    Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

    Get PDF
    Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention
    corecore